120 Chapter 3 31. Lazzaro C, Lopiano L, Cocito D. Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis. Neurol Sci. 2014;35(7):1023-1034. 32. Gelinas D, Katz J, Nisbet P, England JD. Current practice patterns in CIDP: a cross-sectional survey of neurologists in the United States. J Neurol Sci. 2019;397:84-91. 33. Le Masson G, Sole G, Desnuelle C, et al. Home versus hospital immunoglobulin treatment for autoimmune neuropathies: a cost minimization analysis. Brain Behav. 2018;8(2):e00923. 34. Stangel M, Gold R, Pittrow D, et al. Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry. Ther Adv Neurol Disord. 2016;9(3):165-179. 35. CBO. Richtlijn Bloedtransfusie; 2011. https://www.nvog.nl/wp- content/uploads/2018/02/Bloedtransfusie-2.0-11-11-2011-1.pdf. Accesed July 23, 2018. Updated 2019. https://richtlijnendatabase. nl/richtlijn/bloedtransfusiebeleid/startpagina_-_ bloedtransfusiebeleid.html. Accessed August 23, 2021 36. BloodStar. Fetal and neonatal alloimmune thrombocytopenia (FNAIT), 2019. Accessed April 15, 2019. https://www.criteria.blood. gov.au/MedicalCondition/View/2541 37. Lieberman L, Greinacher A, Murphy MF, et al. Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence- based practice, an international approach. Br J Haematol. 2019;185: 549-562. 38. Iro MA, Martin NG, Absoud M, Pollard AJ. Intravenous immunoglobulin for the treatment of childhood encephalitis. Cochrane Database Syst Rev. 2017;10:CD011367. 39. Abboud H, Probasco JC, Irani S, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute man- agement. J Neurol Neurosurg Psychiatry. 2021;92(7):757-768. 40. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immu- nol. 2017;139(3S):S1-S46. 41. Shehata N, Palda VA, Meyer RM, et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. Transfus Med Rev. 2010;24(Suppl 1):S7-s27. 42. Enk AH, Hadaschik EN, Eming R, Fierlbeck G. European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in derma- tology, 2016. 43. Ehsani-Chimeh N, Marinkovich MP. Practice and educational gaps in blistering disease. Dermatol Clin. 2016;34(3):251-256. 44. Forbat E, Ali FR, Al-Niaimi F. Intravenous immunoglobulins in dermatology. Part 2: clinical indications and outcomes. Clin Exp Dermatol. 2018;43(6):659-666. 45. Galli E, Holze N, Frambach Y, Thaci D. Recent clinical development in treating chronic inflammatory skin diseases (psoriasis, atopic der- matitis). Allergologie. 2015;38(3):153-162.
RkJQdWJsaXNoZXIy MTk4NDMw